Non-surgical back of eye disease treatment trialled

Article

The Phase III trial of microplasmin for the treatment of back of the eye disease has been initiated, according to a statement from ThromboGenics NV, the developer of microplasmin.

The Phase III trial of microplasmin for the treatment of back of the eye disease has been initiated, according to a statement from ThromboGenics NV, the developer of microplasmin.

The multicentre MIVI-TRUST (Microplasmin for IntraVitreous Injection-Traction Release without Surgical Treatment) trial will be conducted in Europe and North America, and will evaluate microplasmin versus placebo as an intravitreal treatment of patients with focal vitreomacular adhesion. Approximately 80 centres will enrol approximately 320 patients each, and the primary endpoint is resolution of vitreomacular adhesion at one month.

The studies, which were initiated following promising Phase II results, are planned to be completed by the end of 2010.

Recent Videos
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
© 2024 MJH Life Sciences

All rights reserved.